ScholarLens Back to search
2004•PubMedRequires access

CCR5 antagonists for the treatment of HIV.

Chris Barber

Open publisher page 28 citations

Abstract

The CCR5 chemokine receptor is expressed on a wide range of immune cell types and binding to this receptor mediates cellular entry by the majority of HIV isolates. Blocking viral entry via this receptor reduces the viral load in patients infected with HIV, suggesting that a CCR5 antagonist could become a key component in the treatment of HIV-compromised patients. A number of CCR5 antagonists are currently in clinical trials. This review details the status of leading agents and highlights recent advances in the development of new CCR5 antagonists.

About this research paper

What this paper is about

The CCR5 chemokine receptor is expressed on a wide range of immune cell types and binding to this receptor mediates cellular entry by the majority of HIV isolates. Blocking viral entry via this receptor reduces the viral load in patients infected with HIV, suggesting that a CCR5 antagonist could become a key component in the treatment of HIV-compromised patients. A number of CCR5 antagonists are currently in clinical trials. This review details the status of leading agents and highlights recent advances in the development of new CCR5 antagonists.

Why it matters

OpenAlex reports 28 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The CCR5 chemokine receptor is expressed on a wide range of immune cell types and binding to this receptor mediates cellular entry by the majority of HIV isolates. Blocking viral entry via this receptor reduces the viral load in patients infected with HIV, suggesting that a CCR5 antagonist could become a key component in the treatment of HIV-compromised patients. A number of CCR5 antagonists are currently in clinical trials. This review details the status of leading agents and highlights recent advances in the development of new CCR5 antagonists.

Key concepts: CCR5 receptor antagonist, Chemokine receptor CCR5, Chemokine receptor, Human immunodeficiency virus (HIV), Medicine, Chemokine, Clinical trial, Receptor

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
CCR5 antagonists for the treatment of HIV. — Research Paper | ScholarLens